5-Bromo-6-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid
Names and Identifiers of 1000340-11-3
CAS Number |
1000340-11-3 |
|---|---|
MDL Number |
MFCD09880100 |
IUPAC Name |
5-bromo-6-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid |
InChI |
InChI=1S/C9H7BrN2O2/c1-4-7(10)2-5-6(9(13)14)3-11-8(5)12-4/h2-3H,1H3,(H,11,12)(H,13,14) |
InChIKey |
KLCKTBOCUFDKEF-UHFFFAOYSA-N |
Canonical SMILES |
CC1=C(C=C2C(=CNC2=N1)C(=O)O)Br |
UNSPSC Code |
12352100 |
Physical and chemical properties of 1000340-11-3
Density |
1.8±0.1 g/cm3 |
|---|---|
Exact Mass |
253.969086 |
H Bond Acceptors |
3 |
H Bond Donors |
2 |
Index of Refraction |
1.733 |
LogP |
3.16 |
Molecular Formula |
C9H7BrN2O2 |
Molecular Weight |
255.068 |
PSA |
65.98000 |
Storage condition |
2-8°C |
Safety Information of 1000340-11-3
Applications of 1000340-11-3
5-Bromo-6-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid has several notable applications:
- Medicinal Chemistry: It serves as a key intermediate in synthesizing kinase inhibitors and other pharmacologically active compounds.
- Biological Studies: Utilized in enzyme inhibition assays and receptor binding studies to explore biochemical pathways.
- Chemical Biology: Employed as a chemical probe for studying cellular mechanisms and signaling pathways.
- Industrial
Interaction Studies of 1000340-11-3
Studies on the interactions of 5-Bromo-6-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid with biological targets have demonstrated its potential as an inhibitor of fibroblast growth factor receptors. These interactions are critical for understanding how this compound can modulate cellular processes involved in tumor growth and metastasis. Further research is needed to elucidate the full scope of its interactions and therapeutic potential against various diseases.
Biological Activity of 1000340-11-3
The biological activity of 5-Bromo-6-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid is primarily linked to its interactions with fibroblast growth factor receptors (FGFRs). It has been shown to inhibit FGFR1, FGFR2, and FGFR3, leading to reduced cell proliferation and increased apoptosis in cancer cells. This inhibition is crucial for developing targeted therapies for cancers that exhibit aberrant FGFR signaling.
Additionally, compounds with similar structures have been associated with various biological activities, including anti-inflammatory and anti-cancer properties. The specific mechanisms of action involve modulation of signaling pathways that are critical for cell survival and proliferation.
